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A cross-sectional study of patients living with HIV/
AIDS treated during 2003 to 2007 in decentralized,
rural health centers in Zambia was performed to
measure virological outcomes after 12 months of
antiretroviral therapy and identify factors associated
with virological failure. Data from 228 patients who
started antiretroviral therapy >12 months prior were
analyzed. In all, 93% received stavudine þ lamivudine
þ nevirapine regimens, and median antiretroviral
therapy duration was 23.5 months (interquartile range
2 0 - 2 8 ) .O ft he2 0 5p a ti e n tst es te dfo rvi r all o a d ,1 7 7(8 6%)
had viral load <1000 copies/mL. Probability of developing
virological failure (viral load >1000 copies/mL) was 8.9%
at 24 months and 19.6% at 32 months. Predictors for
virological failure were <100% adherence, body mass
index <18.5 kg/m
2, and women <40 years old. Of those
with virological failure who underwent 3 to 6 months of
intensive adherence counseling, 45% obtained virologi-
cal success. In a remote, resource-limited setting in
decentralized health centers, virological and immunolo-
gical assessments of patients on antiretroviral therapy
>12 months showed that positive health outcomes are
achievable.
Keywords: antiretroviral therapy; HIV; rural health
centers; sub-Saharan Africa; viral load
Introduction
Located in northern Zambia, Nchelenge district of
Luapula Province is a remote, rural, and relatively
poor area with an estimated population of 136 000
people. About 60% of the population live under the
poverty line, with high levels of unemployment, illit-
eracy, maternal mortality (830/100 000 live births),
1
and gender inequality. The health care sector in
Nchelenge is underdeveloped, and HIV prevalence is
high at an estimated rate of 15.2% (adults 15-49 years
old).
1 In 2001, an HIV/AIDS care program was
started in Nchelenge district as part of a collabora-
tive partnership between Me ´decins Sans Frontie `res
(MSF) and the Zambian Ministry of Health (MOH)
with the aim of reducing the high level of related
morbidity and mortality.
The MSF program started in 6 catchment areas
with home-based care (HBC) and information, edu-
cation, and communication (IEC) activities. It
expanded in 2002 to 2003 to include HIV testing and
care in the rural health centers of 6 villages, includ-
ing prevention of mother-to-child transmission
(PMTCT) and antiretroviral therapy (ART). The
program was extended to 2 additional rural health
centers in 2005. By July 2007, more than 1300
HIV-positive patients had been started on ART.
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cal, immunological, and treatment outcomes on ART
were routinely monitored. Although immunological
(eg, CD4 count) and clinical indicators (eg, weight
gain),incidenceofopportunisticinfections (OIs), and
mortality are surrogate measures of ART effective-
ness, it is most accurately predicted by measuring
rates of viral suppression. However, this is not routi-
nely available in resource-limited settings (RLS).
In a recent meta-analysis virological outcomes
from ART programs in Africa have been variable,
ranging from 37% to 84% of patients with undetect-
able viral load (VL) after 12 months.
2 For MSF pro-
grams, undetectable VL rates (<400 copies/mL)
after 12 months have ranged from 75% to 90%.
3-5
However, most of these data come from programs
in large urban centers with better access to
resources. In this study, we aimed to assess the effec-
tiveness of ART in a rural, remote, health center-
based HIV program, by determining the virological
outcomes of patients with at least 12 months of ART
experience in Nchelenge, and to identify factors
associated with poor virological control.
Methods
Study Population
All patients  18 years of age who started ART before
August 31, 2005, and remained on ART in the pro-
gram were eligible for the study. Medical back-
ground and follow-up information were collected
routinely at each consultation on standardized forms
and entered into monitoring software (FUCHIA;
Epicentre, Paris, France).
All patients received free comprehensive HIV
care, including ART, through the rural health
centers. World Health Organization (WHO) prequa-
lified generic antiretroviral (ARV) drugs, mainly as
fixed-dose combination (FDC), were provided. Med-
ical doctors, clinical officers, and nurses of both
MSF and MOH provided the clinical care.
Eligibility criteria for ART were all patients in
WHO clinical stage 4, clinical stage 3 with CD4
<350 cells/mm
3, or clinical stages 1 and 2 with
CD4 <200 cell/mm
3. All who met the criteria,
showed commitment to the program, and were
assessed as likely to reliably take ART were offered
treatment. In addition, prophylaxis (cotrimoxazole)
and treatment of OIs, nutritional support, and
psychosocial support were provided. Patients under-
went intensive adherence counseling by nurse coun-
selors prior to and after commencing ART. Peer
support groups facilitated by adherence counselors
were established at all health centers to provide
psychosocial and socioeconomic support.
Virological Testing and Analysis
In September-October 2006 and February-March
2007, a cross-sectional survey of serum VL was
conducted for all eligible patients on treatment.
Blood samples were collected upon presentation to
the clinic for routine HIV care.
For virological examination, separate plasma
samples were collected (5 mL in EDTA tube) after
centrifugation. Handling time was never >3 hours
between collection and processing. After processing,
the samples were stored at  20 C for no longer than
1 week. All samples were referred frozen to the
Centre for Infectious Diseases Research Zambia
laboratory in Lusaka where VL measurements were
performed using the Roche Amplicor system. CD4
counts were performed using a fluorescence-activated
cell sorting (FACS) count machine.
Virological failure (VF) was defined as a VL
>1000 copies/mL, and virological success (VS) as
VL  1000 copies/mL. Immunological failure was
defined as a CD4 count less than or equal to baseline
after 6 months of ART, a >50% decrease from CD4
peak on therapy, or failure to increase CD4 by
>25 cells/mm
3 over the first year of ART (in the
absence of a transient concomitant infection).
All analyses were performed using the Epi-Info
statistics program and STATA 9.1 software (Stata
Corp, College Station, Tex). Probabilities of develop-
ing VF over time were determined using the Kaplan-
Meier method.
Ethical Considerations
The Research Ethics Committee of the University of
Zambia, Lusaka, approved the research protocol in
August 2006 (Ref: 007-08-06, No: FWA 00000338).
The MSF Ethics Review Board also approved the pro-
tocol in June 2006. Patients were free to accept or
refuse participation in the study and signed a consent
form before inclusion. All patients were informed
about their VL result at their next consultation, and
those with VF received appropriate predefined clinical
follow-up.
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Baseline Characteristics
Total patient cohort. Among all patients on ART at
August 31, 2006, 435 adults had started treatment
more than 12 months previously (Figure 1). Of
these, 262 (60%) were female, 47% had a body mass
index (BMI) <18.5 kg/m
2, and the majority had
advanced stages of immunosuppression: 43% in
WHO clinical stage 3 and 43% in stage 4, and median
baseline CD4 count of 163 cells/mm
3 (interquartile
range [IQR] 88-229; n ¼ 143). Median age at ART
initiation was 36.4 years (IQR 29.6-42.6). Antiretro-
viral therapy regimens included stavudine (d4T) þ
lamivudine (3TC) þ nevirapine (NVP) for 380
patients (88%) and d4T þ 3TC þ efavirenz (EFV) for
45 (10%). Nine (2%) were ART-experienced at their
first ARV prescription in the program, and none were
on second-line therapy.
By the time of the study, after a median duration
on ART of 1.71 years (IQR 0.46-2.24), 112 (26%)
patients had died, 65 (15%) were lost to follow-up
(LFU), 6 (1%) had interrupted treatment, and 24
(6%) were transferred out. The 12-month mortality
rate was 18%, with 82% of these deaths occurring
within the first 6 months of treatment. Six-month
mortality rates decreased from 18% in 2004 to 7%
in 2006. The 12-month LFU rate was 12%, with
62% of these patients lost within 6 months of
commencing treatment. The remaining 228 (52%)
patients alive and on ART were included in the
study.
Cohort of patients remaining on ART. Baseline
characteristics of the 228 patients remaining on ART
are shown in Table 1. As with the total cohort popu-
lation, the majority of patients still on ART were in
advanced stages of immunosuppression at baseline
(89% WHO clinical stage 3 or 4; median CD4
count 163 cells/mm
3). Median duration of ART
was 23.5 months with most patients (213; 93%)o n
d4T þ 3TC þ NVP at the time of study.
None of the 228 patients refused VL testing, but
23 (10%) did not have VL performed because the
collecting team was not present at the time of the
patient’s visit. However, this group of patients was
reported to be 100% adherent to ART. No significant
differences were observed in the characteristics of
those who had their VL measured compared with
those who did not (Table 1).
Virological Outcomes
Of the 205 VL samples analyzed, 177 (86%) met the
criteria for VS (Table 2). The probability of develop-
ing VF was 8.9% at 24 months, and 19.6% at
32 months (Figure 2). Baseline characteristics for
those with VS and VF are shown in Table 3, with
significant differences between the groups for
median CD4 counts (P ¼ .03) and median BMI
(P ¼ .03). Two patients died just after VL was taken;
both had VL >200 000 copies/mL and were known to
be adhering poorly to treatment. Two patients had
confirmed malaria just before VL was taken (VL of
8270 and 6440 copies/mL, respectively).
Immunological Outcomes
CD4counts were obtained on the same dayas theVL
sampleforallbut1patient(204/205;99.5%).Median
CD4 count at the time of study was 455 cells/mm
3:
this was significantly greater for the VS group
(488 cells/mm
3; IQR 349-586) than the VF group
(263 cells/mm
3; IQR 197-400; P < .001). Overall
median CD4 gain at the time of the study was
294 cells/mm
3, with a median gain of 301 cells/mm
3
for those with VS, compared with 162 cells/mm
3 for
those with VF (P < .01).
Less than 1% and 9% of patients had aCD4 count
persisting <50 and <200 cells/mm
3, respectively.
ART initiation >12 months
(Oct 2003 to Aug 2005)
N = 435
Death = 112
Lost to follow-up = 65
Interrupted treatment = 6







Figure 1. Flowchart of patients included in virological
assessment. ART, antiretroviral therapy; VL, viral load.
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CD4 count <200 cells/mm
3 compared with those
with VF (odds ratio [OR] 0.20, 95% CI 0.06-0.65).
Eight patients showed evidence of immunological
failure during the study. Immunological failure was
24 times more likely in those with VF (6 patients)
compared with those with VS (2 patients; OR 23.7,
95% CI 4.0-182.7).
Anthropometric Outcomes
At >12 months on ART, median BMI was 20.8 kg/m
2
(IQR 18.8-22.5; n ¼ 129). Patients with VS had a
significantly higher median BMI (21.1 kg/m
2; IQR
19.6-23.0) than patients with VF (19.8 kg/m
2; IQR
18.7-21.6; P ¼ .02).
Predictors of VF
Most of the baseline characteristics (duration of
treatment, ART regimen, WHO clinical stage, clinic
site, distance living from the clinic, occupation) were
not associated with VF (Table 3). Tuberculosis (TB)
was specifically examined, but no association was
found.
Multivariate logistic regression analysis showed that
adherence <100% (P ¼ .02) and BMI <18.5 kg/m
2 at
baseline (P ¼ .01) were positive predictors of VF
(Table 4). An interaction between age and sex was
observed in predicting those who were more at risk
of VF (Table 4). Women >40 years of age were the
least likely (OR 0.49), whereas women <40 years
were most likely to have VF (OR 2.62). However,
men >40 years were more likely to have VF as
opposed to men <40 years (OR 2.1).
Follow-up of Patients With VF
Eleven of the 14 patients with VF in September 2006
were followed up after their VL result was obtained
(1 could not be traced, and 2 had died). After 3 to
6 months of close monitoring and intensive adher-
ence counseling, 5 (45%) of the 11 patients achieved
VS, and overall 7 (63%) had a decrease in VL levels.
Four patients (27%) had an increase in VL and were
Table 1. Characteristics of Patients Remaining on ART, With or Without VL
Characteristic VL Performed (n ¼ 205)
VL Not
Performed (n ¼ 23) Total (n ¼ 228)
a P Value
Sex M ¼ 86, F ¼ 119 M ¼ 7, F ¼ 16 M ¼ 93, F ¼ 135 .29
Median age, years (IQR
b) 38 (34-46) 36 (33-45) 38 (34-45) .58
WHO clinical stage at ART baseline I ¼ 9, II ¼ 14, III ¼ 124,
IV ¼ 58
I ¼ 1, II ¼ 1, III ¼ 15,
IV ¼ 6







161 (103-217) 174 (96-317) 163 (103-232) .26
ART regimen



















19.0 (17.6-21.0) 20.0 (17.6-21.8) 19.1 (17.6-21.6) .28
Abbreviations: 3TC, lamivudine; ART, antiretroviral therapy; AZT, zidovudine; BMI, body mass index; d4T, stavudine; EFV, efavirenz;
F, female; M, male; NFV, nelfinavir; NVP, nevirapine; VL, viral load; WHO, World Health Organization.
a Not all characteristics have the same number of patients.
b IQR, interquartile range (25%-75%).
c ART regimen at date of viral load test.
Table 2. Viral Load Measurements of Patients on
ART >12 Months
Viral Load (Copies/mL) N % 95% CI
 1000 177 86.4 81-91
>1000 to <10 000 9 4.4 2-8
 10 000 to <30 000 3 1.4 0-4
 30 000 16 7.8 5-12
Total 205 100
Abbreviation: CI, confidence interval.
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Discussion
Our study of patients with HIV/AIDS cared for
through rural health centers in Nchelenge, Zambia,
demonstrated positive outcomes for those alive and
taking ART for more than 12 months. An estimated
86% of these patients had VS, and immunological
gains were robust, with only 9% remaining at risk
of life-threatening OIs or disease (CD4 <200 cells/
mm
3).
These results compare favorably with other MSF
HIV/AIDS programs and were similar to or better
than other studies inRLS.
5-8 Although ART has been
shown to be successfully provided in these settings,
with adherence to treatment equivalent or better
than that in more developed settings,
4 most of these
data come from large urban centers in RLS. In this
study, we show that similar outcomes can be
achieved in a remote, rural region of southern Africa,
with treatment and care provided through decentra-
lized primary health care centers.
Several factors likely contributed to these results.
First, access to health care was increased by
decentralizing care to rural health centers closer to
patients’ homes, and by providing all HIV/AIDS
treatment free of charge. Second, the effectiveness
of the ART regimens were aided by the use of WHO
prequalified generic FDC ARV drugs that ensured
the quality of the drugs and adherence-friendly low
pill burdens. Third, emphasis was placed on patient
education, literacy, and empowerment with respect
to the provision of ART, and peer support was available
through the formation of support groups. Fourth,
people were supplied with supplementary food,
which provided nutritional and socioeconomic
support. Finally, MSF provided resources, training,
and logistical support to the MOH, initially via a
parallel service, to ensure quality care and an unin-
terrupted ARV drug supply.
Of note, although positive immunological out-
comes were achieved even in those with VF (median
CD4 gain at time of study: 148 cells/mm
3), these
results were not as robust as those with VS. In addi-
tion, VF patients were 5 times more likely to remain
at risk of life-threatening OIs or disease (CD4 count
<200 cells/mm
3). These findings demonstrate that
people with virologically failing regimens do obtain
benefit from treatment (compared with no treatment),
but nevertheless improved results can be obtained if
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Figure 2. Probability of virological success by time on ART. ART, antiretroviral therapy.
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remained alive and in the program; significant num-
bers of patients died (18% at 12 months) or were
LFU (12% after 12 months). Thus, a selection bias
may have been present in our study as virological
suppression rates are likely to be lower in those who
died or were LFU. In fact, early mortality rates on
ART were high, especially in 2004 when ART activ-
ities started (18% at 6 months). Nevertheless, high
mortality rates during the first year of ART have been
reported from several other RLS countries.
7,9,10
Most deaths (82%) occurred within the first
6 months of treatment, likely related to late initiation
of ART when the patient was severely immunosup-
pressed. In addition, high rates of malnutrition and
TB coinfection likely played roles, and immune
reconstitution or adverse events from ART may have
contributed. However, as cause of death was not
Table 3. Baseline Characteristics of Patients With VL Performed
Characteristic Virological Success (n ¼ 177)
a Virological Failure (n ¼ 28) Total (n ¼ 205)
b P Value
Sex M ¼ 74, F ¼ 103 M ¼ 12, F ¼ 16 M ¼ 86, F ¼ 119 .92
Median age, years (IQR
c) 39 (35-46) 37 (30-42) 38 (34-46) .21
WHO clinical stage at ART
baseline
I ¼ 9, II ¼ 12, III ¼ 105,
IV ¼ 51







164 (112-232) 115 (75-169) 161 (103-217) .03
ART-experienced 5 0 5 1.0
ART regimen















23 (20-28) 25 (20-27) 24 (20-28) .45
Median BMI, kg/m
2,
at ART baseline (IQR)
19.0 (18.0-22.0) 18.0 (16.6-19.2) 19.0 (17.6-21.0) .03
Distance from clinic, km <1 ¼ 32; 1-5 ¼ 108;
6-10 ¼ 20; >10 ¼ 17
<1 ¼ 4; 1-5 ¼ 21;
6-10 ¼ 1; >10 ¼ 2
<1 ¼ 36; 1-5 ¼ 129;
6-10 ¼ 21; >10 ¼ 19
.47
Marital status Single ¼ 28; married ¼ 92;
divorced ¼ 38;
widowed ¼ 19
Single ¼ 6; married ¼ 16;
divorced ¼ 4; widowed ¼ 2
Single ¼ 34; married ¼ 108;
divorced ¼ 42; widowed ¼ 21
.68
TB treatment starting ART 16 3 19 .35
TB treatment during ART 7 2 9
TB treatment at time of VL 9 0 9
Abbreviations: 3TC, lamivudine; ART, antiretroviral therapy; AZT, zidovudine; BMI, body mass index; d4T, stavudine; EFZ, efavirenz;
NFV, nelfinavir; NVP, nevirapine; TB, tuberculosis; WHO, World Health Organization.
a Samples with very low levels of HIV, for this study <400 copies/mL, were classified as having ‘‘undetectable’’ viral load.
b Not all characteristics have the same number of patients.
c IQR, interquartile range (25%-75%).
d ART regimen at date of viral load test.
Table 4. Predictors of Virological Failure
Variable/Category Odds Ratio 95% CI P Value
Men <40 years of age (reference group) 1
Men >40 years 2.1 0.46-9.21 .34
Women <40 years 2.62 0.66-10.4 .17
Women >40 years 0.49 0.07-3.3 .46
Adherence <100% (reference: 100% adherence) 4.1 1.21-13.7 .02
Baseline BMI <18.5 kg/m
2 (reference:  18.5 kg/m
2) 3.2 1.26-7.93 .01
Abbreviations: BMI, body mass index; CI, confidence interval.
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correlations. Over time, mortality rates decreased
(from 18% in 2004 to 7% in 2006 after 6 months
of ART), which likely resulted from earlier diagnosis
and treatment of HIV and OIs (especially TB) and
increasing experience in managing HIV by health
staff.
As expected, adherence of <100% was the stron-
gest predictor of VF (OR 4.1), reaffirming the need
for excellent adherence to achieve optimal treatment
outcomes. This poses a formidable challenge for
patients in RLS, especially if faced with stigma and
barriers to accessing treatment, and underlines
the need for intensive adherence strategies to be
implemented in those identified having suboptimal
adherence.
Our results also showed that patients with a base-
line BMI <18.5 kg/m
2 were more likely to develop
VF after 12 months on ART. Although the reasons
for this result are not clear, coexistent conditions
leading to ARV drug malabsorption may be contri-
buting factors. Nevertheless, this finding may thus
help identify patients at increased risk of failure who
should be more closely monitored while on ART.
Gender and age were also found to be predictors
of VF. The majority of women with VF were <40
years old and were at higher risk (OR ¼ 2.6) than
men <40 years, whereas older women were less likely
to have VF than men <40 years (OR ¼ 0.49).
Although we do not have definitive data to support
this, it is postulated that younger women are less
likely to disclose their HIV status and are more likely
to face abandonment, stigma, and discrimination,
negatively affecting treatment adherence. In contrast,
older women may have better adherence because
their position in the community is often stronger,
allowing them an increased ability to make their own
decisions and care for themselves.
11 However, we
found men >40 years had increased rates of VF
(OR ¼ 2.1) compared with men <40 years of age.
It is possible that older men have weaker support sys-
tems than younger men, contributing to reduced ART
adherence. However, some evidence suggests that
older age is a risk factor for increased rates of VF,
12
so older men may simply respond less well to ART.
Some patients will failtreatment on first-line ART
over time, and second-line ART will be needed.
13
Although no patients in our study required second-
line therapy, and numbers requiring second-line
across all MSF programs are relatively small (6% of
patients switched to second-line after 48 months),
14
this has been influenced by the lack of routine viro-
logical monitoring in RLS. It is known that patients
with VL >10 000 copies/mL are at increased risk of
clinical and immunological failure if they continue
their current regimen.
15 Thus, for the 9% of our
cohort with VL >10 000 copies/mL, consideration
should be given to switching to second-line therapy
on the basis of VF alone (assuming intensive counsel-
ing and adherence support were properly provided).
However, this is limited by the many obstacles to
second-line ART in RLS, including high costs,
limited availability of newer, more potent drugs
(including heat-stable formulations of boosted pro-
tease inhibitors), and adherence challenges from the
lack of fixed-dose regimens not requiring food restric-
tions. Such obstacles need to be urgently addressed.
Important to note is that in nearly one half of the
patients studied, VF resolved after 3 to 6 months of
intensive adherence counseling. Thus, initial failure
was likely due to adherence rather than significant
antiviral resistance. This must be comprehensively
addressed, because if adherence is suboptimal, virolo-
gically failing patients will respond no better to second-
line ART and will be at risk of prematurely exhausting
all their effective ARV drug options through the
development of resistance to second-line therapies.
Viral load measurement is an important monitor-
ing tool as evidence from RLS suggests that clinical
and immunological failure has poor sensitivity and
specificity for detecting VF.
16 Thus, reliance on clin-
ical information can result in delayed detection of
treatment failure, which can lead not only to an
increased risk of clinical disease progression but also
a risk of ARV resistance due to ongoing ARV drug
exposure in the presence of high levels of viral repli-
cation. In the presence of limited second-line options,
such resistance mutations (eg, thymidine analogue
mutations [TAMs]) may jeopardize the effectiveness
of second-line ART regimens.
17 Therefore, adapted,
affordable, and reliable means of measuring VL in
RLS are needed for detecting early treatment failure.
Our study has a number of limitations. First,
23 patients had no VL measurement performed.
As the majority of these people were traders who
traveled out of the area on a regular basis, these
patients may have had more difficulty adhering to
treatment. However, against this postulation is the
fact that all these patients had visited the clinics
during the time of the VL study, were all reported
to be 100% adherent to ART, and showed no indica-
tion of illness or other specific problems.
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with time on ART varying between patients. We were
therefore unable to determine exact rates of VF at
any specific time points, and this lack of information
needs to be considered when making comparisons
with other studies where VL is prospectively mea-
sured at defined time points (eg, 24 months).
Based on our study findings in Nchelenge,
Zambia, we conclude that HIV/AIDS treatment and
care delivered free of charge through decentralized
and remote rural health centers can result in positive
outcomes when patients are on ART for more than
12 months. In addition, BMI and adherence rates
<100% can be useful as predictors for VF.
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